4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 113 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 2.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $200,832 | +541.9% | 9,568 | +874.3% | 0.00% | +200.0% |
| Q1 2024 | $31,287 | -84.0% | 982 | -89.8% | 0.00% | -50.0% |
| Q4 2023 | $195,002 | +1269.0% | 9,625 | +760.1% | 0.00% | – |
| Q3 2023 | $14,244 | -74.0% | 1,119 | -63.1% | 0.00% | -100.0% |
| Q2 2023 | $54,788 | +37947.2% | 3,032 | -63.8% | 0.00% | -60.0% |
| Q1 2023 | $144 | +73.5% | 8,366 | +124.4% | 0.01% | +66.7% |
| Q4 2022 | $83 | -99.8% | 3,728 | -15.3% | 0.00% | +200.0% |
| Q3 2022 | $35,000 | -27.1% | 4,401 | -36.2% | 0.00% | 0.0% |
| Q2 2022 | $48,000 | +77.8% | 6,903 | +287.4% | 0.00% | – |
| Q1 2022 | $27,000 | -66.7% | 1,782 | -52.0% | 0.00% | -100.0% |
| Q4 2021 | $81,000 | -3.6% | 3,709 | +19.7% | 0.00% | -50.0% |
| Q3 2021 | $84,000 | +265.2% | 3,099 | +219.5% | 0.00% | +100.0% |
| Q2 2021 | $23,000 | -11.5% | 970 | +60.6% | 0.00% | – |
| Q1 2021 | $26,000 | – | 604 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |